BioCentury | Jan 25, 2016
Strategy

Formative years

...way over our skis and will lose money," noted Nelsen. For example, Arch helped found Xcyte Therapies Inc....
BioCentury | May 7, 2007
Finance

Global visibility

...Opportunity Ltd. In just over 12 months since emigrating to the U.S. and reversing into Xcyte Therapies Inc....
BioCentury | Sep 4, 2006
Company News

Biomira management update

...Hired: Robert Kirkman as president, CEO and a director, formerly acting president and CEO of Xcyte Therapies Inc....
BioCentury | Aug 30, 2006
Company News

Biomira names Kirkman CEO

...director. BRA also appointed Christopher Henney chairman. Previously, Kirkman was acting president and CEO of Xcyte...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...Cyclacel Pharmaceuticals Inc. (CYCC, Short Hills, N.J.), which migrated from the U.K. by merging into Xcyte Therapies Inc....
BioCentury | May 1, 2006
Finance

Ebb & Flow

...month that saw the BioCentury 100 Index fall 10%. Last December, CYCC reverse merged into Xcyte...
BioCentury | Apr 28, 2006
Financial News

Cyclacel raises $45.3 million

...placement agents. CYCC was created through a reverse-merger announced in December between Cyclacel Group and Xcyte...
BioCentury | Apr 3, 2006
Company News

Cyclacel Group plc, Xcyte deal

...form Cyclacel Pharmaceuticals Inc. (see BioCentury, Dec. 19, 2005). Cyclacel Group plc , Dundee, U.K. Xcyte Therapies Inc....
BioCentury | Mar 20, 2006
Company News

Dendreon management update

...Cancer Hired: Mark Frohlich as VP of clinical affairs, formerly VP and medical director at Xcyte Therapies Inc....
BioCentury | Jan 16, 2006
Strategy

IPO in disguise

...NCST) 12/22/05 $45.0 $10.00 $180.8 $181.3 0% Theravance (THRX) 10/5/04 $98.4 $16.00 $817.6 $1,249.4 53% Xcyte...
Items per page:
1 - 10 of 99
BioCentury | Jan 25, 2016
Strategy

Formative years

...way over our skis and will lose money," noted Nelsen. For example, Arch helped found Xcyte Therapies Inc....
BioCentury | May 7, 2007
Finance

Global visibility

...Opportunity Ltd. In just over 12 months since emigrating to the U.S. and reversing into Xcyte Therapies Inc....
BioCentury | Sep 4, 2006
Company News

Biomira management update

...Hired: Robert Kirkman as president, CEO and a director, formerly acting president and CEO of Xcyte Therapies Inc....
BioCentury | Aug 30, 2006
Company News

Biomira names Kirkman CEO

...director. BRA also appointed Christopher Henney chairman. Previously, Kirkman was acting president and CEO of Xcyte...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...Cyclacel Pharmaceuticals Inc. (CYCC, Short Hills, N.J.), which migrated from the U.K. by merging into Xcyte Therapies Inc....
BioCentury | May 1, 2006
Finance

Ebb & Flow

...month that saw the BioCentury 100 Index fall 10%. Last December, CYCC reverse merged into Xcyte...
BioCentury | Apr 28, 2006
Financial News

Cyclacel raises $45.3 million

...placement agents. CYCC was created through a reverse-merger announced in December between Cyclacel Group and Xcyte...
BioCentury | Apr 3, 2006
Company News

Cyclacel Group plc, Xcyte deal

...form Cyclacel Pharmaceuticals Inc. (see BioCentury, Dec. 19, 2005). Cyclacel Group plc , Dundee, U.K. Xcyte Therapies Inc....
BioCentury | Mar 20, 2006
Company News

Dendreon management update

...Cancer Hired: Mark Frohlich as VP of clinical affairs, formerly VP and medical director at Xcyte Therapies Inc....
BioCentury | Jan 16, 2006
Strategy

IPO in disguise

...NCST) 12/22/05 $45.0 $10.00 $180.8 $181.3 0% Theravance (THRX) 10/5/04 $98.4 $16.00 $817.6 $1,249.4 53% Xcyte...
Items per page:
1 - 10 of 99